Thus, using the VEGFR2 inhibitor SU5416 and the NAB to block VEGF-A/VEGFR2 signaling, our data suggest that VEGF-A acts directly on medulloblastoma cells in an autocrine manner to promote cell migration and invasion. Here, KDR is linked to medulloblastoma.